TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Schrodinger Inc (SDGR)

Healthcare Health Information Services
15.10 $
-1.4% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Schrodinger Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Momentum & Trend

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
15.40$
Open
15.30$
Day High
15.50$
Day Low
14.80$
Volume
1,217,095shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
11.10 $ 22.50 $
03/30/2026 10/24/2025

Current price 15.10 $ — 35% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
1.1$B
Shares Outstanding
66Mio.
Float
87.9%
Beta
1.6

Performance

Perf. 1M
22.80%
Perf. 3M
56.90%
Perf. 6M
-5.40%
YTD Performance (%)
-15.90%
52-Week-High Distance
-32.0%
Perf. 1Y
-25.53%
Perf. 3Y
-71.06%
Perf. 5Y
-77.63%
Perf. Since Inception
-47.14%

Technical Indicators

MA 38 Days
15.60$
MA 50 Days
15.30$
MA 200 Days
15.20$
RSI (14)
46.2
Volatility 30 Days
42.5%
Volatility 250 Days
51.6%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
0.0
PEG
P/B
3.7
P/S
4.5
EV/EBITDA
-10.8
Price/FCF

Profitability

Gross Margin
55.3%
EBIT Margin
Net Margin
-40.6%
Return on Equity
-30.1%
Return on Assets
-15.0%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
0.3
Altman Z″
2.70
weak
Piotroski
2 out of 9

Growth

Sales Growth Last Quarter
-1.60%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
23.29%
Forward Sales Growth
12.77%
Forward EPS Growth
29.70%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
3
RS Rating
32
EPS Rating
42
weak
Piotroski
2 out of 9
Fundamental Rating
D (40 out of 100)
Altman Z″
2.70

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

4 of 10 Weak growth

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years 12.2% failed
  • More than 10% revenue growth is expected for the coming year 12.8% passed
  • Share count grows by less than 3% a year 1.1% passed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 28.2% failed
  • Gross margin at 40% or higher and without meaningful erosion 55.7% failed
  • Goodwill from acquisitions does not grow faster than revenue 0.7% passed
  • Net debt below twice EBITDA 286 m net cash passed
  • Operating cash flow covers the profits of the last three years -31 m failed
  • Return on capital at 15% or higher, or up versus two years ago -31.1% failed
  • Insiders hold at least 10% or are net buyers 2.9% failed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 15.10 $
Price Target (average) 20.57 $

The price target sits 36.2% above the current price.

Consensus
Sell
Analyst Ratings
8
Distribution of Recommendations
Strong Buy 6
Buy 0
Hold 2
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -2.25 -2.25 – -2.25 235 -11.3% 1
12/31/2027 -1.66 -1.66 – -1.66 265 26.2% 1

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

5. Aug 2026 · after the close · Q2 2026
Expected Earnings per Share
-0.60 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 88.3 $M Q4 2025: Q1 · 59.6 $M Q1 2025: Q2 · 54.8 $M Q2 2025: Q3 · 54.3 $M Q3 2025: Q4 · 87.2 $M Q4 2026: Q1 · 58.6 $M Q1

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.55 88 19.10 -45.50 -31 -32
2025: Q1 -0.82 60 62.70 -100.40 144 144
2025: Q2 -0.59 55 15.70 -78.80 -52 -53
2025: Q3 -0.45 54 53.90 -60.40 -62 -62
2025: Q4 0.44 87 -1.20 37.30 -16 -16
2026: Q1 -0.81 59 -1.60 -102.50 -15 -17
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2017 56 -19 -17 -3.07 -15 -45 58
2018 67 -28 -28 -0.59 -24 -72 121
2019 86 -39 -25 -0.39 -26 -93 155
2020 108 -61 -24 -0.41 17 624 746
2021 138 -111 -100 -1.42 -71 557 756
2022 181 -147 -149 -2.10 -120 448 689
2023 217 -177 41 0.54 -137 549 803
2024 208 -209 -187 -2.58 -157 421 823
2025 256 -167 -103 -1.41 14 364 726

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Schrödinger, Inc. entwickelt zusammen mit seinen Tochtergesellschaften eine physikbasierte Rechenplattform, die die Entdeckung neuartiger Moleküle für die Arzneimittelentwicklung und Materialanwendungen in den USA, im asiatisch-pazifischen Raum, in Europa, im Nahen Osten, in Afrika und international ermöglicht.

CEO Insider Trades (12 Mo.)selling own stock
Employees850
HeadquartersNew York, NY
Address1540 Broadway, 10036 New York, United States
Phone212 295 5800
Websiteschrodinger.com
IPO Date6. Feb 2020
ISINUS80810D1037

Management

Management
Name Title Birth Year
Ramy Farid Ph.D. CEO, President & Director 1965
Karen Akinsanya Ph.D. President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships 1968
Richard A. Friesner Ph.D. Co-Founder, Scientific Advisory Chairman and Director 1953
Richie Jain Executive VP, CFO & Treasurer 1985
Yvonne Tran Esq. Corporate Secretary, Chief Legal & People Officer 1971
Prof. William Goddard III, Ph.D. Co-Founder & Scientific Advisor
Kenneth Patrick Lorton Executive VP, CTO & COO of Software 1984
Therese Abrams Principal Accounting Officer 1984
Shane Brauner Executive VP & Chief Information Officer 1977
Jaren Irene Madden Chief Corporate Affairs Officer & Head of Investor Relations

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
16. Jul 2026 Jain Rachit EVP & CFO Sell 875 15.60 13,647

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?